Continuous venovenous hemofiltration combined with hemoperfusion for toxic epidermal necrolysis: a retrospective cohort study

References

• Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.
   PubMed Web of Science ®Google Scholar
• Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87–96.
   PubMedGoogle Scholar
• Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:e181–16, quiz 203–184.
   PubMed Web of Science ®Google Scholar
• Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol. 1996;135:305–6.
   PubMed Web of Science ®Google Scholar
• Jarrett P, Rademaker M, Havill J, et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol. 1997;22:146–7.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Boridy I, Mazhar M, et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J. 1996;89:1001–3.
   PubMed Web of Science ®Google Scholar
• Velez A, Moreno JC. 2002; Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol. 46:469–70.
   PubMed Web of Science ®Google Scholar
• Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146:707–9.
   PubMed Web of Science ®Google Scholar
• Inamo Y, Okubo T, Wada M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol. 2002;127:89–94.
   PubMed Web of Science ®Google Scholar
• Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218–21.
   PubMed Web of Science ®Google Scholar
• Yamada H, Takamori K, Yaguchi H, et al. 1998; A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher. 2:153–6.
   PubMedGoogle Scholar
• Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458–61.
   PubMed Web of Science ®Google Scholar
• Kostal M, Blaha M, Lanska M, et al. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher. 2012;27:215–20.
   PubMed Web of Science ®Google Scholar
• Gonchar DI. [Hemosorption in the intensive treatment of Lyell's disease]. Anesteziol Reanimatol. 1983;6:61–2.
   PubMedGoogle Scholar
• Muravko LS, Dorozhkova IA, Tolkachev BG. [Use of hemosorption in a 10-month-old infant with Lyell’s syndrome]. Pediatriia. 1988;1:94.
   PubMedGoogle Scholar
• Vozgoment OV, Griaznov VN, Medvedev SL. [Experience with the use of hemosorption in the intensive therapy of Stevens-Johnson syndrome in a child]. Anesteziol Reanimatol. 1989;6:46–7.
   PubMedGoogle Scholar
• Wang YM, Tao YH, Feng T, et al. Beneficial therapeutic effects of hemoperfusion in the treatment of severe Stevens-Johnson syndrome/toxic epidermal necrolysis: preliminary results. Eur Rev Med Pharmacol Sci. 2014;18:3696–701.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med. 1993;21:522–6.
   PubMed Web of Science ®Google Scholar
• Peng Z, Pai P, Hong-Bao L, et al. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients. Cytokine. 2010;50:186–91.
   PubMed Web of Science ®Google Scholar
• Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:e171–13, quiz 85–76.
   Web of Science ®Google Scholar
• Polson J, Lee WM. & American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–97.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for acute kidney injury. Kidney Inter. 2012;2:1–138.
   Web of Science ®Google Scholar
• Huang C, Zhang P, Du R, et al. Treatment of acute hypernatremia in severely burned patients using continuous veno-venous hemofiltration with gradient sodium replacement fluid: a report of nine cases. Intensive Care Med. 2013;39:1495–6.
   PubMed Web of Science ®Google Scholar
• Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126:272–6.
   PubMed Web of Science ®Google Scholar
• Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81–8.
   PubMedGoogle Scholar
• Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87:144–8.
   PubMed Web of Science ®Google Scholar
• Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26–32.
   PubMed Web of Science ®Google Scholar
• Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33–6.
   PubMedGoogle Scholar
• Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167:424–32.
   PubMed Web of Science ®Google Scholar
• Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114:1209–15.
   PubMed Web of Science ®Google Scholar
• Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118:728–33.
   PubMed Web of Science ®Google Scholar
• Sun S, He L, Bai M, et al. High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study. Ann Saudi Med. 2015;35:352–8.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wang SR, Su W, et al. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2010;14:596–602.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wang SR, Yang ZL, et al. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2013;17:454–61.
   PubMed Web of Science ®Google Scholar
• Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801.
   PubMed Web of Science ®Google Scholar
• Saotome T, Endo Y, Sasaki T, et al. A case of severe acute pancreatitis treated with CTR-001 direct hemoperfusion for cytokine apheresis. Ther Apher Dial. 2005;9:367–71.
   PubMed Web of Science ®Google Scholar
• Kobe Y, Oda S, Matsuda K, et al. Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif. 2007;25:446–53.
   PubMed Web of Science ®Google Scholar
• Zollo A, Cavatorta F, Galli S. Ultrasound-guided cannulation of the femoral vein for acute hemodialysis access with silicone catheters. J Vasc Access. 2001;2:56–9.
   PubMedGoogle Scholar
• Bai M, Zhou M, He L, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med. 2015;41:2098–110.
   PubMed Web of Science ®Google Scholar